$2.16
2.49% today
Nasdaq, Apr 01, 06:49 pm CET
ISIN
US56600D1072
Symbol
MRVI

Maravai LifeSciences Stock price

$2.21
-1.01 31.37% 1M
-6.10 73.41% 6M
-3.24 59.45% YTD
-6.39 74.30% 1Y
-33.06 93.73% 3Y
-27.64 92.60% 5Y
-27.64 92.60% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
-0.15 6.36%
ISIN
US56600D1072
Symbol
MRVI
Sector
Industry

Key metrics

Market capitalization $317.47m
Enterprise Value $623.68m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.41
P/S ratio (TTM) P/S ratio 1.22
P/B ratio (TTM) P/B ratio 0.96
Revenue growth (TTM) Revenue growth -10.30%
Revenue (TTM) Revenue $259.19m
EBIT (operating result TTM) EBIT $-68.05m
Free Cash Flow (TTM) Free Cash Flow $-23.43m
Cash position $322.40m
EPS (TTM) EPS $-1.03
P/E forward negative
P/S forward 1.65
EV/Sales forward 3.23
Short interest 9.61%
Show more

Is Maravai LifeSciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Maravai LifeSciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Maravai LifeSciences forecast:

7x Buy
47%
7x Hold
47%
1x Sell
7%

Analyst Opinions

15 Analysts have issued a Maravai LifeSciences forecast:

Buy
47%
Hold
47%
Sell
7%

Financial data from Maravai LifeSciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
259 259
10% 10%
100%
- Direct Costs 172 172
14% 14%
66%
87 87
37% 37%
34%
- Selling and Administrative Expenses 79 79
1% 1%
30%
- Research and Development Expense 19 19
11% 11%
7%
-11 -11
127% 127%
-4%
- Depreciation and Amortization 57 57
17% 17%
22%
EBIT (Operating Income) EBIT -68 -68
844% 844%
-26%
Net Profit -145 -145
22% 22%
-56%

In millions USD.

Don't miss a Thing! We will send you all news about Maravai LifeSciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Maravai LifeSciences Stock News

Neutral
PRNewsWire
about 19 hours ago
NEW YORK , March 31, 2025 /PRNewswire/ --  Why: Rosen Law Firm, a global investor rights law firm, reminds of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2025 lead plaintiff deadline. So what: If you purchased Maravai securities during the Class Per...
Neutral
PRNewsWire
one day ago
LOS ANGELES , March 31, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ: MRVI) have opportunity to lead the securities fraud class action lawsuit.
Neutral
PRNewsWire
4 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Maravai LifeSciences To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Maravai LifeSciences between August 7, 2024 and February 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilso...
More Maravai LifeSciences News

Company Profile

Maravai Lifesciences Holdings, Inc. operates as an investment holding company. It develops biopharmaceuticals. The company is headquartered in San Diego, CA.

Head office United States
CEO William Martin
Employees 570
Founded 2014
Website www.maravai.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today